157 related articles for article (PubMed ID: 24939834)
1. Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation.
Fetih G; Fathalla D; El-Badry M
Drug Dev Res; 2014 Jun; 75(4):257-66. PubMed ID: 24939834
[TBL] [Abstract][Full Text] [Related]
2. Development of ibuprofen nanoliposome for transdermal delivery: Physical characterization, in vitro/in vivo studies, and anti-inflammatory activity.
Gaur PK; Bajpai M; Mishra S; Verma A
Artif Cells Nanomed Biotechnol; 2016; 44(1):370-5. PubMed ID: 25211229
[TBL] [Abstract][Full Text] [Related]
3. Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Kaur K; Jain S; Sapra B; Tiwary AK
Curr Drug Deliv; 2007 Oct; 4(4):276-82. PubMed ID: 17979648
[TBL] [Abstract][Full Text] [Related]
4. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.
Baboota S; Shakeel F; Ahuja A; Ali J; Shafiq S
Acta Pharm; 2007 Sep; 57(3):315-32. PubMed ID: 17878111
[TBL] [Abstract][Full Text] [Related]
5. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
Jain SK; Gupta Y; Jain A; Bhola M
Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
[TBL] [Abstract][Full Text] [Related]
6. Tulsi oil as a potential penetration enhancer for celecoxib transdermal gel formulations.
Shamsher AA; Charoo NA; Rahman Z; Pillai KK; Kohli K
Pharm Dev Technol; 2014 Feb; 19(1):21-30. PubMed ID: 23281713
[TBL] [Abstract][Full Text] [Related]
7. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
Padamwar MN; Pokharkar VB
Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured lipid carrier (NLC) based gel of celecoxib.
Joshi M; Patravale V
Int J Pharm; 2008 Jan; 346(1-2):124-32. PubMed ID: 17651933
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
[TBL] [Abstract][Full Text] [Related]
10. Effect of non-phospholipid-based cationic and phospholipid-based anionic nanosized emulsions on skin retention and anti-inflammatory activity of celecoxib.
Tamilvanan S; Baskar R
Pharm Dev Technol; 2013; 18(4):761-71. PubMed ID: 23668371
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib.
Bragagni M; Mennini N; Maestrelli F; Cirri M; Mura P
Drug Deliv; 2012; 19(7):354-61. PubMed ID: 23043648
[TBL] [Abstract][Full Text] [Related]
12. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
[TBL] [Abstract][Full Text] [Related]
13. Phycocyanin liposomes for topical anti-inflammatory activity: in-vitro in-vivo studies.
Manconia M; Pendás J; Ledón N; Moreira T; Sinico C; Saso L; Fadda AM
J Pharm Pharmacol; 2009 Apr; 61(4):423-30. PubMed ID: 19298687
[TBL] [Abstract][Full Text] [Related]
14. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
16. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
Wen MM; Farid RM; Kassem AA
J Liposome Res; 2014 Dec; 24(4):280-9. PubMed ID: 24779560
[TBL] [Abstract][Full Text] [Related]
17. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery.
El-Menshawe SF; Hussein AK
Pharm Dev Technol; 2013; 18(4):779-86. PubMed ID: 21913880
[TBL] [Abstract][Full Text] [Related]
18. Design and development of liposomes for colon targeted drug delivery.
Gupta AS; Kshirsagar SJ; Bhalekar MR; Saldanha T
J Drug Target; 2013 Feb; 21(2):146-60. PubMed ID: 23373543
[TBL] [Abstract][Full Text] [Related]
19. Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels.
Petit A; Sandker M; Müller B; Meyboom R; van Midwoud P; Bruin P; Redout EM; Versluijs-Helder M; van der Lest CH; Buwalda SJ; de Leede LG; Vermonden T; Kok RJ; Weinans H; Hennink WE
Biomaterials; 2014 Sep; 35(27):7919-28. PubMed ID: 24952978
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
